Compare 10X Genomics Inc (TXG) vs Exxon Mobil Corporation (XOM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
10X Genomics Inc vs Exxon Mobil Corporation — how do they compare? 10X Genomics Inc trades at $47.2 (market cap $5.48B), while Exxon Mobil Corporation trades at $151.71 (market cap $614.94B). The key difference: Exxon Mobil Corporation is far larger — about 112.2× 10X Genomics Inc's market cap, and Exxon Mobil Corporation pays a 2.78% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals.
| TXG | XOM | |
|---|---|---|
Market Cap | $5.48B | $614.94B |
Sector | Health | Energy |
52-Week High | $45.80 | $171.52 |
52-Week Low | $11.34 | $105.83 |
Enterprise Value | $5.02B | $654.17B |
Dividend Yield | — | 2.78% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TXG trades at $47.20, up 7.91% on the day, with a bullish technical signal from moving averages. The company reported Q1 2026 revenue that beat estimates, and net losses have narrowed significantly from -$255M in 2023 to -$44M in 2025. Operating cash flow turned strongly positive at $136M in 2025. Recent developments include the acquisition of Proteintech Genomics and a collaboration with Cleveland Clinic on bladder cancer diagnostics.
The outlook is mixed; improving fundamentals and strategic expansions support growth, but persistent net losses and a high EV/EBITDA of 133.91 pose valuation risks. Analyst consensus is divided with a $39.14 price target below the current price, indicating caution despite a majority buy/hold ratings.
ExxonMobil (XOM) trades at $147.39, up 0.99% today, with a bullish technical signal from moving averages and oscillators. The stock has beaten earnings estimates for the last three quarters, though revenue and net income have trended lower since 2022. Analyst consensus is a buy with a $169.78 price target, and recent news highlights the company's Permian Basin advantage and potential oil price spikes.
XOM offers value through strong cash flow and a robust balance sheet, but faces headwinds from declining profitability and net cash outflows. Investment appeal hinges on oil price stability and execution in key growth areas, while risks include volatile energy markets and execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →About Exxon Mobil Corporation
Exxon Mobil Corporation operates petroleum and petro chemicals businesses. The Company provides operations include exploration and production of oil and gas, electric power generation, and coal and minerals operations. Exxon Mobil also manufactures and markets fuels, lubricants, and chemicals. Exxon Mobil serves customers worldwide.
Read more on XOM →
